Dr. Ludlam has received an educational grant from Novo Nordisk, has acted as medical advisor for Ipsen, a consultant for Biogen Idec and JQ1 cell line Baxter as well as Bayer, from which he has also received funding to attend medical conferences. Dr. Mauser-Bunschoten has received unrestricted research funding from CSL Behring, is a speaker for Bayer, Sanquin Bloedvoorziening, and Novo Nordisk, and has received funding for postmarketing surveillance by Wyeth and Baxter. Dr. Poon has attended advisory board meetings of CSL Behring, Novo Nordisk, Octapharma, and Pfizer. He has attended sponsored meetings on behalf of Baxter and Bayer,

is a speaker for Pfizer, and acted as chair of Novo Nordisk’s expert Selleckchem Inhibitor Library panel on Glanzmann’s Thrombasthenia registry. The other authors have no competing interests to declare. Question Step 1 (Level 1) Step 2 (Level 2) Step 3 (Level 3) Step

4 (Level 4) Step 5 (Level 5) OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o = 5653. Systematic review of surveys that allow matching to local circumstances “
“Summary.  Until now, the World Federation of Haemophilia (WFH) has focused its energies on the development of initiatives to enhance the clinical care of persons with bleeding disorders around the world. While this objective will still represent the main goal of this organization, there

is interest in launching a new program that focuses on international research into the inherited bleeding disorders. This project will begin with the development of a clinical outcomes research competition and will incorporate ADP ribosylation factor a complementary research mentorship program. During the 50 years since the founding of the World Federation of Haemophilia (WFH), major advances have been made in the clinical management of inherited bleeding disorders. Significant progress has been made in the diagnosis, classification, treatment and long-term care of individuals with these conditions and as we enter the second decade of this new Millennium, the future for further enhancements in care looks very bright. All of these advances in clinical management have derived from research into these conditions, and as we strive to further improve the care of these individuals, the support of inherited bleeding disease research should continue to be a major priority for the global community. Many people involved in the clinical management of individuals with bleeding disorders provide outstanding medical care to these subjects, but never engage in research. As the diagnosis, treatment and follow-up of persons with these conditions has expanded to involve multidisciplinary teams of health care professionals, the standard of overall care has progressively improved and details of the clinical management have been increasingly refined.